🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,027 results for “ERA” Clear

  1. SPD476

    Takeda

    Ulcerative Colitis

    phase 3 small molecule completed

    1 trial

  2. SPD476 (mesalazine)

    Takeda

    Colitis, Ulcerative

    phase 3 small molecule completed

    1 trial

  3. SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine

    Takeda

    Ulcerative Colitis

    phase 3 small molecule completed

    1 trial

  4. SPD489

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    2 trials

  5. SPD503 (1 mg)

    Takeda

    Attention Deficit Disorder With Hyperactivity

    phase 3 small molecule completed

    1 trial

  6. SPD503 (Guanfacine hydrochloride) (2 mg)

    Takeda

    Attention Deficit Disorder With Hyperactivity

    phase 3 small molecule completed

    1 trial

  7. SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM

    Ars Pharmaceuticals Irl Limited

    Amyotrophic Lateral Sclerosis

    phase 3 small molecule completed

    1 trial

  8. SPN-810

    SUPERNUS PHARMACEUTICALS, INC.

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule terminated

    2 trials

  9. SPN-810

    SUPERNUS PHARMACEUTICALS, INC.

    Attention Deficit Hyperactivity Disorder

    phase 3 small molecule terminated

    1 trial

  10. SPN-810 (18 mg)

    SUPERNUS PHARMACEUTICALS, INC.

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    2 trials

  11. SR-A + Epratuzumab

    United Therapeutics Europe Ltd

    Acute Lymphoblastic Leukemia (ALL)

    phase 3 small molecule completed

    1 trial

  12. SRP-4045

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 3 small molecule completed

    2 trials

  13. SRP-9003

    Sarepta Therapeutics

    Limb-girdle Muscular Dystrophy

    phase 3 mab active

    2 trials

  14. SRP-9005

    Sarepta Therapeutics

    Muscular Dystrophies, Limb-Girdle

    phase 3 mab terminated

    1 trial

  15. STK-001, STK-001

    Stoke Therapeutics

    Dravet syndrome

    phase 3 small molecule active

    1 trial

  16. SV-BR-1-GM

    BriaCell Therapeutics

    Breast Cancer

    phase 3 mab active

    2 trials

  17. Saline, 0.9% sodium chloride solution IV infusion marketed authorized will be used as the placebo and will be supplied by the site. the SmPC previously authorized are Country specific. for Belgium, Spain and Sweden per local requirements under CTDs no SmPCs were submitted., Delandistrogene moxeparvovec-rokl

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 3 small molecule active

    1 trial

  18. Saphnelo 300 mg concentrate for solution for infusion, Anifrolumab Placebo

    AstraZeneca AB

    Active Proliferative Lupus Nephritis

    phase 3 small molecule active

    1 trial

  19. Sativex®

    Jazz Pharmaceuticals Ireland Limited

    Detrusor Overactivity

    phase 3 small molecule completed

    1 trial

  20. Selinexor

    Karyopharm Therapeutics Inc

    Endometrial Cancer

    phase 3 small molecule active

    2 trials

  21. Selinexor

    Karyopharm Therapeutics Inc

    Dedifferentiated Liposarcoma

    phase 3 small molecule completed

    1 trial

  22. Selinexor

    Karyopharm Therapeutics Inc

    Multiple Myeloma

    phase 3 small molecule active

    12 trials

  23. Selinexor (combination therapy)

    Karyopharm Therapeutics Inc

    Relapsed/Refractory Diffuse Large B-cell Lymphoma

    phase 3 small molecule active

    1 trial

  24. Sephience 250 mg oral powder in sachet, Sephience 1 000 mg oral powder in sachet

    PTC THERAPEUTICS, INC.

    Phenylketonuria

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources